Slides
Page 1
1 1 Edgewise Therapeutics The 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 Kevin Koch, CEO
Page 2
2 Forward Looking Statement This presentation contains contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this presentation that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, Edgewise’s product candidates and programs, including sevasemten, EDG-7500, EDG-15400 and its cardiovascular programs; statements regarding the ability of the Company to establish sevasemten as the first approved therapy, becoming a commercial company and executing the first-in-disease launch in Becker; statements regarding bringing transformative medicines to patients; statements regarding the market opportunity for sevasemten in Becker an EDG-7500 ; statements regarding Edgewise’s expectations relating to its clinical trials, including timing of the completion of the GRAND CANYON trial, finalizing design for the Company’s Phase 3 program in obstructive and nonobstructive HCM, timing of reporting data (including top-line data of sevasemten, Phase 2 results for EDG-7500 in HCM, the presentation of data from the GRAND CANYON trial and the presentation of data from the Phase 1 trial of EDG-15400) and timing of initiation of clinical trials (including Phase 3 trials in individuals with HCM and Duchenne and Phase 2 trial of EDG-15400); statements regarding Edgewise’s ability to advance its pipeline; statements regarding the company’s ability to achieve milestones; statement regarding the company’s cash runway; risks associated with Edgewise gaining further insights from its analysis of trial results over time; and statements regarding Edgewise’s timing for filing a New Drug Application with the FDA for sevasemten in Becker. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. The forward-looking statements contained herein are based upon Edgewise’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those projected in any forward- looking statements due to numerous risks and uncertainties, including but not limited to: risks associated with Edgewise’s limited operating history, its products being early in development and not having products approved for commercial sale; risks associated with Edgewise not having generated any revenue to date; Edgewise’s ability to achieve objectives relating to the discovery, development and commercialization of its product candidates, if approved; Edgewise’s need for substantial additional capital to finance its operations; Edgewise’s substantial dependence on the success of sevasemten and EDG- 7500; Edgewise’s ability to develop and commercialize sevasemten, EDG-7500 and EDG-15400, and discover, develop and commercialize product candidates in its cardiovascular and cardiometabolic future programs; risks related to Edgewise’s clinical trials of its product candidates not demonstrating safety and efficacy; risks related to Edgewise’s product candidates causing serious adverse events, toxicities or other undesirable side effects; the outcome of preclinical testing and early clinical trials not being predictive of the success of later clinical trials and the risks related to the results of Edgewise’s clinical trials not satisfying the requirements of regulatory authorities; delays or difficulties in the enrollment and/or maintenance of patients in clinical trials; risks related to failure to capitalize on other indications or product candidates; risks related to competition; risks relating to interim, top-line and preliminary data from Edgewise’s clinical trials changing as more patient data becomes available; risks related to failure to develop a proprietary drug discovery platform; risks related to exposure to additional risk if we develop sevasemten and potential other programs in connection with other therapies; risks related to production of drugs by Edgewise’s third-party manufacturers; risks related to changes in methods of product candidate manufacturing or formulation; risks related to not achieving adequate market acceptance; risks related to the patient population for our product candidates having a small patient population; risks related to the regulatory approval processes of domestic and foreign authorities being lengthy, time consuming and inherently unpredictable; risks relating to disruptions at the FDA, the SEC and other government agencies; risks relating to Edgewise’s ability to attract and retain highly skilled executive officers and employees; Edgewise’s ability to obtain and maintain intellectual property protection for its product candidates; Edgewise’s reliance on third parties; risks related to future acquisitions or strategic partnerships; risks related to general economic and market conditions; and other risks. These forward-looking statements are made as of the date of this presentation, and Edgewise assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.
Page 3
3 3 Global leader in muscle disease therapeutic development ● Combined expertise in muscle biology and small molecule drug discovery built our novel and differentiated muscle-focused platform Unwavering patient commitment ● Patients and families are critical voices in all development programs Rapidly advancing portfolio ● Pipeline of novel therapeutics for muscular dystrophies and serious cardiac conditions
Page 4
4 Strong 2025 Execution Positions 2026 as a Potentially Transformational Year for Edgewise Positive EDG-7500 Topline Data in HCM Positive Sevasemten Topline Data Progress Across CV Pipeline Strong Financial Position ❑ In Becker, completed enrollment of pivotal GRAND CANYON and reported positive top-line data from the MESA Phase 2 OLE ❑ In Duchenne, reported positive LYNX and FOX Phase 2 results ❑ Announced completion of CIRRUS-HCM 28-day Phase 2 Parts B & C ❑ Initiated CIRRUS-HCM 12-week Part D arm in oHCM and nHCM and announced favorable interim safety results ❑ Initiated Phase 1 study with EDG-15400 in healthy adults, intended for future studies in HFpEF ❑ Strengthened balance sheet with $200M financing ending the year with over half billion in cash and runway through 2028 Abbreviations: HCM, Hypertrophic cardiomyopathy; oHCM, obstructive hypertophic cardiomyopathy; nHCM, nonobstructive hypertrophic cardiomyopathy; Becker, Becker muscular dystrophy; Duchenne, Duchenne muscular dystrophy; HFpEF, Heart Failure with Preserved Ejection Fraction; OLE, open label extension
Page 5
5 Our Pipeline Abbreviations: Becker, Becker muscular dystrophy; Duchenne, Duchenne muscular dystrophy; HFpEF, Heart Failure with Preserved Ejection Fraction Becker Duchenne Preclinical Phase 1 Phase 2 Pivotal / Phase 3 Regulatory Submission Hypertrophic Cardiomyopathy EDG-7500 Undisclosed cardiac sarcomeric target Sevasemten Myosin ATPase Muscular Dystrophy EDG-003 Undisclosed target Cardiometabolic EDG-15400 Undisclosed cardiac sarcomeric target HFpEF Cardiovascular
Page 6
6 Poised to Become a Commercial Company in 2027 Sevasemten Pivotal GRAND CANYON Data in Becker Anticipated End of Year
Page 7
7 Becker is a Devastating Disease With No Therapeutic Options ❑ Becker is a rare, genetic, life-shortening, debilitating and degenerative neuromuscular disease ❑ Progressive contraction-induced muscle damage results in loss of skeletal muscle function, and severe disability ❑ Individuals with Becker lose mobility, function and independence in the prime of their lives Bryan, living with Becker ❑ There are currently no FDA approved therapies for Becker muscular dystrophy Abbreviations: Becker, Becker muscular dystrophy
Page 8
8 Sevasemten is an Orally Administered First-in-Class Fast Skeletal Myosin Inhibitor Novel MOA, oral administration, generally safe and well tolerated across multiple trials Targets fast myosin; intended to protect dystrophic muscle against contraction-induced Injury Intended to minimize progressive muscle damage that leads to functional impairment Unique MOA Addresses root cause of muscle breakdown Potential first ever therapy for Becker Abbreviations MOA, mechanism of action
Page 9
9 Significant Clinical Experience with Sevasemten Drives Confidence in Pivotal GRAND CANYON • Durable response • 11 of 12 remain on therapy • Longest exposure +4 yrs • Well tolerated Phase 1: 24-month Open Label Study (N=12) COMPLETE Phase 2: 16-weeks Placebo Controlled Exercise Challenge Study (N=9) COMPLETE Pivotal Cohort: 18-month Placebo Controlled Study (N=175 Adults) ACTIVE, Not Recruiting Phase 2: 12-month Placebo Controlled Study (N=40 Adults) COMPLETE • Significant reduction in biomarkers of muscle damage vs placebo • Well tolerated • Met primary endpoint reduction in CK • NSAA stable over time with trend toward improvement vs placebo • Well tolerated • Primary endpoint powered at >98% to show a statistically significant NSAA difference at 18 months Open-label extension study in adults/adolescents with Becker; 99% of eligible Becker trial participants have chosen to enroll Abbreviations: Becker, Becker muscular dystrophy
Page 10
10 Even a 1-Point Decline in Function can Have Detrimental Effects on Individuals Living with Becker From using the toilet independently… …to asking for help to get up from the toilet. …to requiring assistance from another person or mobility device. …to requiring someone else’s help to get back up. From using stairs or steps… From being able to get up from a fall… For individuals living with Becker, preserving function and preventing even a 1-Point NSAA decline could look like: Abbreviations: NSAA, North Star Ambulatory Assessment; Becker, Becker muscular dystrophy
Page 11
11 Sustained Stability in ARCH Participants After 3 Years of Treatment with Sevasemten vs a Predicted -4.4 Point Decline *Data on file. * Subject with meniscal tear at month 15 excluded from subsequent NSAA measures Means and 95% CI shown for Safety Population. NHx comparators not available for time points earlier than 12 months Abbreviations: NSAA, North Star Ambulatory Assessment; OLE, open label extension 0 6 1 2 18 2 4 3 0 3 6 - 4 - 2 0 Months Total NSAA Score (change from baseline) +4 +2 NSAA score at 3 yrs: +0.2* Predicted NSAA decrease: -4.4 Sevasemten Predicted NSAA trajectory based on baseline characteristics 12 Months in MESA OLE NSAA Score Change from Baseline +4.6 Mean change difference vs predicted
Page 12
12 After Transitioning to MESA, CANYON Participants Positively Diverged from Predicted NSAA Declines 0 3 6 9 12 15 18 -3 -2 -1 0 Months Total NSAA Score (change from baseline) +2 +1 Through Month 12, LS Means and 95% CI shown for Safety Population Post-Month 12 timepoints, observed means and 95% CI are presented Abbreviations: NSAA, North Star Ambulatory Assessment; OLE, open label extension Predicted NSAA trajectory based on baseline characteristics -2.2 predicted NSAA decrease @ 18 months NSAA Score Change from Baseline +0.8 vs baseline +0.2 since initiation of sevasemten Participants remain blinded to initial treatment assignment Sevasemten 6 Months in MESA OLE
Page 13
13 21 of 27 of Patients Demonstrated a Greater Increase in NSAA Scores at Month 12 Compared to Their Predicted Trajectories -4 -2 0 Month 12 DNSAA (sevasemten - predcited control) +2 +4 +6 +8 Sevasemten Month 12 NSAA Observed-Predicted* (predicted NSSA response normalized to zero) Mean Difference= 1.3 (p-value=0.0031) Sevasemten treatment better Predicted NSAA trajectory better *Data not available for one sevasemten-treated participant Median improvement of +1.5 NSAA points Abbreviations: NSAA, North Star Ambulatory Assessment; OLE, open label extension 1 2 73 4 5 6 8 9 1410 11 12 13 15 16 2117 18 19 20 22 23 24 25 26 27 Subjects
Page 14
14 Sevasemten Observations to Date Reinforce Confidence in a Positive GRAND CANYON Readout in 4Q26 Abbreviations: R, randomization; PO, by mouth; NSAA, North Star Ambulatory Assessment; MRI, magnetic resonance imaging 9 15 PRIMARY ENDPOINT NSAA at 18 months KEY INCLUSION CRITERIA Adult individuals with Becker with NSAA 5-32, not taking corticosteroids ENROLLMENT 175 Study design - 18 months 10mg PO dailyScreening 0 1 3 6 Additional Endpoints Timed function tests (TFTs), biomarkers of muscle damage, MRI, patient reported outcomes (PROs), safety Month GLOBAL REGISTRATIONAL COHORT 12 POWERED AT >98% for observing a significant difference assuming a mean NSAA difference of 1.7 points over placebo at 18 months Placebo R 2:1 18
Page 15
15 BRAND Readiness ORGANIZATION Readiness MARKET Readiness Sharpening understanding of the Becker unmet need and executing targeted education to drive awareness and improve the patient journey in Becker Across Edgewise, building cross-functional capabilities, talent, and scalable operating infrastructure to support launch execution Advancing clinical evidence of sevasemten, defining the brand platform, and preparing to deliver value to patients, HCPs, and payers MARKETING • Launch and go-to- market strategy • Disease state education and awareness • Brand building MARKET ACCESS • Value proposition and evidence package • Payor engagement • Distribution model • Patient support strategy MEDICAL AFFAIRS • Thought leader engagement • Medical education • Scientific publications and congresses PATIENT ADVOCACY • Advisory & PAG engagement • Disease state education • Community events SALES • Targeting and customer segmentation • Field force sizing and deployment • Talent acquisition strategy COMMERCIAL ORGANIZATION FOCUS: Commercial Activities Advancing to Ensure Successful Preparation of the Market, Organization and Brand
Page 16
16 Our Early Commercial Planning Provides a Strong Foundation to Support a Substantial Market Opportunity in Becker ~ 6,000 Becker patients in the US; >12,000 in major market Zero FDA approved therapies; total potential Becker market ~$5 Billion Ambulatory patients diagnosed with Becker Sevasemten Initial Target Population Large Prevalent Population Market Opportunity Market research indicates high degree of physician awareness of sevasemten and significant demand for a Becker therapy Survey Question: “How likely would you be to reach out to patients who have been lost to follow-up if Product X (sevasemten) was approved?” ~90% of physicians surveyed will reach out to their Becker patients previously lost to follow-up post-approval of sevasemten Enthusiasm for Sevasemten Sources: Bluestar Primary Research and Analysis; Salari, Nader, et al. Journal of orthopedic surgery and research 17.1 (2022): 1-12; Theadom, Alice, et al. Neuroepidemiology 43.3-4 (2014); Pagola-Lorz, Inmaculada, et al. Orphanet Journal of Rare Diseases 14.1 (2019): 1-13; Nakagawa M, et al. Neuroepidemiology. 1991;10(4):185-191.
Page 17
17 Poised to Win in HCM Strong ‘7500 Clinical Data and Differentiated MOA Drive Phase 3 Strategy to Unlock Broad Market Opportunity
Page 18
18 Hypertrophic Cardiomyopathy (HCM) is a Severe Inherited Heart Disease Brian, living with HCM ❑ Severe and progressive, patients present with shortness of breath, fatigue and chest pains and are often misdiagnosed ❑ A significant unmet need remains for therapies without a HF risk, able to improve symptoms and enhance QoL ❑ There are two forms of HCM, obstructive (oHCM) and nonobstructive (nHCM) ❑ Current targeted treatments are only approved for oHCM (none for nHCM) and have limitations due to their MOA Abbreviations: MOA, mechanism of action; QoL, quality of life; HF, heart failure
Page 19
19 Unmet Need Remains High in HCM Due to Intrinsic Mechanistic Limitations of CMIs Abbreviations: HCM, hypertrophic cardiomyopathy; nHCM, nonobstructive hypertrophic cardiomyopathy; oHCM, obstructive hypertrophic cardiomyopathy; CMI, cardiac myosin inhibitor; REMS, risk evaluation and mitigation strategies; MOA, mechanism of action; HF, heart failure 1. Ommen SR et al. Circulation. 2024;149(23):e1239-e1311; 2. Maron MS et al. N Engl J Med. 2024;390:1846-61; 3. CAMZYOS [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2023; 4. MYQORZO [package insert]. South San Francisco, CA: Cytokinetics; 5. Olivotto I et al. Lancet. 2020;396(10253):759-769. 6. Edgewise market research 7. Guidepoint interviews with CAMZYOS prescribers. No approved therapies for nHCM: risk limits efficacy Some limitation in symptom improvement reported by patients 6-7 Suboptimal patient experience: frequent visits, echo monitoring 1-4 Burden for prescribers: REMS requirement 1-5 Risk of Heart Failure (inherent to CMI MOA) Black Box Warning for HF 3-4 mavacamten and aficamten
Page 20
20 EDG-7500 is a Cardiac Sarcomere Modulator Slows contraction and enhances relaxation, without inhibiting peak myosin contractile force, which improves overall diastolic function * Based on preclinical and clincal data with EDG-7500 Abbreviations: HCM, hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; MOA, mechanism of action Minimal Changes in LVEF* Emerging Clinical Profile Encouraging preclinical and clinical results to date support a differentiated LVEF profile and positive patient-reported feel and function results Novel MOA* EDG-7500 is designed to avoid excessive drops in systolic performance In clinical studies to date this has translated into no clinically meaningful changes in LVEF or reductions in LVEF to below <50%
Page 21
21 Administration of Fixed Dose ‘7500 Demonstrated Rapid, Multi- Domain Improvement Across HCM Clinical Manifestations Mean ± SEM * Represents 7 individuals who were evaluated for NYHA at week 4 5 participants had either resting gradients <30 mmHg or Valsalva gradients <50 mmHg on Day 1; ** % reaching LVOT criteria based on N=7 and N=9 participants with Week 4 data at 50 mg and 100 mg respectively; Complete LVOT-G response defined as resting and Valsalva gradients <30 mmHg and <50 mmHg, respectively. EOS, end of study; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire; KCCQ-CSS, KCCQ-Clinical Summary Score; LVOT-G, left ventricular outflow tract gradient; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association oHCM, obstructive hypertrophic cardiomyopathy. 0 20 40 60 80 100 Study Visit Resting LVOT-G (mmHg) Day 1 Wk1 Wk2 Wk4 EOS 30 0 20 40 60 80 100 120 140 Study Visit Valsalva LVOT-G (mmHg) Day 1 Wk1 Wk2 Wk4 EOS 50 -100 -80 -60 -40 -20 0 20 Study Visit % Change from Baseline Day 1 Wk1 Wk2 Wk4 EOS Improvements in LV Diastolic Function ~89% of oHCM Patients Showed a Complete LVOT-G Response at 100 mg 56% achieved NT-proBNP <150 pg/mL at 100mg Rest Valsalva 89% with Clinical Improvements at 100 mg dose 43% 78% 0% 20% 40% 60% 80% 100% 50 mg (N=7) 100 mg (N=9) Patients achieving ≥ 1 NYHA Class improvement KCCQ-CSS oHCM
Page 22
22 88% of nHCM Participants Treated with ‘7500 had a KCCQ-CSS Clinical Improvement EOS, end of study; KCCQ-CSS, Kansas City Cardiomyopathy Questionnaire; KCCQ-CSS, KCCQ-Clinical Summary Score; KCCQ-OSS, Overall Summary Score; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association nHCM, nonobstructive hypertrophic cardiomyopathy Edgewise Therapeutics – Data on file; Means ± Std Err presented * 2 patients at 4 weeks Note: To-date, no head-to-head comparisons of any other products to any of our product candidates in any clinical trial have been completed; results have been obtained from different trials with different designs, endpoints and patient populations; results may not be comparable. Ahmad Masri Presentation at World Congress on Acute Heart Failure, 20 May 2023: Evaluation of Aficamten in Patients with Symptomatic N on obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4; Ho C et al., JACC, Volume 75, Issue 21, 2 June 2020, Pages 2649-2660 55% reduction in NT-proBNP by Week 1 88% with Clinical Improvements -100 -50 0 50 Study Visit % Change from Baseline Day 1 Wk1 Wk2 Wk4 EOS -40 -20 0 20 40 60 80 Study Visit % Change from Baseline Day 1 Wk1 Wk2 Wk4 EOS Rapid e’ Changes in as Early as One Week 50mg Dose Group (n=6) 100mg Dose Group (n=2) 0 20 40 60 80 100 78 73 63 51 KCCQ Clinical Summary Score (KCCQ-CSS) D=16 D=22 Robust absolute improvements in KCCQ-CSS NT-proBNP Change in e’ KCCQ-CSS nHCM
Page 23
23 CIRRUS-HCM Part D, a 12-Week Study of ‘7500 in Both oHCM and nHCM Part D: 12 weeks goal-directed dose escalation to optimize efficacy and tolerability Week D1 2 4 8 12 Efficacy assessments: NT-proBNP, Cardiac Troponin I, KCCQ, NYHA and LVOT-G (oHCM only); LVEF also assessed 72 On Optimized Stable Dose Long-Term Extension 25 mg QD 150 mg QDAdults with oHCM (including some from Part B) .50 mg QD 100 mg QD Adults with nHCM (including some from Part C) Dose Optimization: Based on LVOT-G (oHCM) or NT-proBNP (nHCM) CIRRUS-HCM Open-Label Study to Evaluate the Safety, Tolerability, PK, and PD of EDG-7500 in Adults With HCM PART D – KEY INCLUSION CRITERIA NYHA II-III, KCCQ-CSS < 85, LVEF ≥ 0.60, NT-proBNP ≥300 pg/mL oHCM: LVOT-G ≥ 50 mmHg at rest or Valsalva nHCM: LVOT < 30 mmHg at rest and Valsalva < 50 mmHg ENROLLMENT TARGET 50-60 PRIMARY ENDPOINT Safety 2-weeks 2-weeks 4-weeks 4-weeks Abbreviations: LVOT, left ventricular outflow tract; NYHA, New York Heart Association; KCCQ, Kansas City Cardiomyopathy Questionnaire; LVEF, left ventricular ejection fraction; PK, pharmacokinetic; PD, pharmacodynamic; QD, once daily; HCM; hypertrophic cardiomyopathy; oHCM, obstructive hypertrophic cardiomyopathy; nHCM, nonobstructive hypertrophic cardiomyopathy 6
Page 24
24 No Correlation Observed Between ‘7500 Plasma Concentration and LVEF Change Across a Broad Exposure Range 0 100 200 300 400 500 600 700 800 900 1000 1100 1200 -30 -20 -10 0 10 20 30 EDG-7500 Plasma Concentration (ng/ml) LVEF Change from Baseline (%) Placebo SAD/MAD HV oHCM (CIRRUS Parts A & B) nHCM (CIRRUS Part C) CIRRUS Parts B (oHCM) & C (nHCM) (25 mg) CIRRUS Part D (oHCM & nHCM) Pooled Healthy Volunteer, CIRRUS Part A, B, C and D * Data – No LVEF Drops <50% Data cutoff date: 2025-12-23 Healthy volunteers received doses of placebo or 5 -300 mg in the SAD and placebo or 25 -100 mg in the MAD CIRRUS Part A participants received single doses of 50 mg, 100 mg and 200 mg; CIRRUS Part B and C participants received fixed dose of either 25 mg, 50 mg or 100 mg; CIRRUS Part D participants received 25 -200 mg * Part D data based on site read echos; pending core lab data Abbreviations: LVEF, left ventricular ejection fraction; SAD, single ascending dose; MAD, multiple ascending dose; HCM, hyper trophic myopathy; oHCM, obstructive HCM; nHCM, nonobstructive HCM; HV, healthy volunteers
Page 25
25 ‘7500’s TPP Uniquely Resonates with Broader Range of Prescribers Including General Cardiologists and KOLs at COEs HCM Patients Managed by Cardiologists Key: oHCM patients nHCM patients 1 2 3 4 HCM Clinics Academic Cardiology CoEs High Volume Community Cardiology Community Cardiology EDG-7500 Future Potential CMIs Today (Black Box Warning and LVEF Monitoring requirements limit reach) Volume of HCM Patients Source: Bluestar Market Research; Edgewise Blinded Guidepoint Interviews Abbreviations: LVEF, left ventricular ejection fraction; HCM, hypertrophic myopathy; oHCM, obstructive HCM; nHCM, nonobstructive HCM; CMI, cardiac myosin inhibitor; KOL, key opinion leader; COE, center of excellence; TPP, target product profile
Page 26
26 A Lack of Systolic Liability and Favorable Diastolic Properties (“Lusitropy”) Could Allow ‘7500 to Capitalize on the HCM Market ~165K symptomatic HCM patients in US; ~125K oHCM and ~40K nHCM (and growing!) Zero approved therapies in nHCM; total potential HCM market ~$10 Billion Symptomatic oHCM / nHCM across all clinical settings where HCM patients are managed EDG-7500 Target Population Large Prevalent Population Market Opportunity Survey Question: Consider a future world where additional treatment options are available for HCM. What factors would most likely influence your decision to select a specific treatment for your HCM patients? Enthusiasm for 7500 “With this type of safety profile, you’re already out ahead of what is available.” - Cardiologist Unmet need in HCM remains high due to logistics and safety requirements of CMI’s Source: Bluestar Primary Research and Analysis; Abbreviations: HCM; Abbreviations: HCM; hypertrophic cardiomyopathy; oHCM, obstructive hypertrophic cardiomyopathy; nHCM, nonobstructive hypertrophic cardiomyopathy; LVEF, left ventricular ejection fraction; REMS, risk mitigation and Top three attributes associated with EDG-7500: • Efficacy in oHCM & nHCM • Favorable LVEF profile; potential for no REMs • Well-tolerated - Survey Respondents
Page 27
27 Strong Financial Position: Well Capitalized to Execute Critical Value Generating Milestones
Page 28
28 Well-Capitalized to Execute Across Sevasemten, EDG-7500 and EDG-15400 Programs *As of September 30, 2025 (1)DEBT $0 CASH, CASH EQUIVALENTS & MARKETABLE SECURITIES* ~$563M COMMON SHARES OUTSTANDING (NASDAQ: EWTX) ~105M CASH RUNWAY EXPECTED THROUGH 2028
Page 29
29 Edgewise Pipeline is Rich in Anticipated Near-Term, Value- Creating Catalysts Abbreviations: HV, healthy volunteers; oHCM, obstructive hypertrophic cardiomyopathy; nHCM, non-obstructive hypertrophic cardiomyopathy; CV, cardiovascular; HFpEF, Heart Failure with Preserved Ejection Fraction; NDA, New Drug Application H1 2026 H2 2026 H1 2027 Muscular Dystrophy Sevasemten Cardiac Hypertrophic Cardiomyopathy P2 CIRRUS-HCM Part D in oHCM & nHCM EDG-7500 P3 Initiation oHCM & nHCM P1 EDG-15400 HV Data EDG-15400 P2 Data in HFpEFHeart Failure Duchenne Becker P3 Trial Planning and Initiation GRAND CANYON Registrational Cohort Readout NDA Submission EDG-15400 P2 Initiation in HFpEF
Page 30
30 Building Blocks in Place to Deliver Against Two Highly Differentiated Late-Stage Clinical Programs in 2026 SEVASEMTEN Transforming into a commercial-ready company in preparation for a potential first-in- disease launch in Becker EDG-7500 Plan and execute a Phase 3 program to unlock the opportunity across a broad HCM population WELL CAPITALIZED Poised to independently execute across all value generating milestones in both Becker and HCM
Page 31
Leaders in Muscle Disease Science Headquartered in beautiful Boulder, Colorado, with expert teams spanning the globe, we are dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases